Business
Ginkgo Bioworks in Partnership with STRM.BIO and University of British Columbia in Project to Develop In Vivo CAR Therapies Under ARPA-H's EMBODY Program
Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineeri
About this update from Ginkgo Bioworks Holdings, Inc.
[{"type":"text","content":"Ginkgo Bioworks to apply its RNA construct design expertise to develop long-lived, tissue-specific, and highly potent in vivo CAR therapies for autoimmune diseases","length":164,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, Oct. 23, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced a collaboration with STRM.BIO and the University of British Columbia (UBC) as part of the Advanced Research Projects Agency for Health's (ARPA-H) Engineering of Immune Cell Inside the Body (EMBODY) program. EMBODY is led by ARPA-H Program Manager Daria Fedyukina, Ph.D. The partnership aims to develop in vivo chimeric antigen receptor (CAR) therapies for autoimmune diseases, leveraging Ginkgo's expertise in RNA construct design and immune cell engineering.","length":554,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Ginkgo Bioworks)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Ginkgo Bioworks)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":200,"url":"https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/pD7D8Jpi1nYhM2EkNRaAzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM1MztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fe3c2abd5acfb0739db965e53a5bec87","width":400,"height":200}},"href":"https://mma.prnewswire.com/media/1583909/Ginkgo_Logo_Lockup.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Autoimmune diseases, such as systemic lupus erythematosus (SLE) and myasthenia gravis (MG), affect millions of people worldwide and pose significant public health challenges. These conditions are characterized by the immune system mistakenly attacking the body's own cells, leading to chronic inflammation and tissue damage. Current treatments often involve systemic immunosuppression, which can result in increased risks of infection and other side effects due to broad immune suppression.","length":494,"tagName":"p"},{"type":"text","content":"The project, titled "IN VIvo T-cell Engineering with Megakaryocyte EVs" (INVITE-ME), focuses on developing in vivo CAR-T therapies for autoimmune diseases by combining STRM.BIO's proprietary megakaryocyte-derived extracellular vesicle (MV) delivery system with Ginkgo's RNA construct design expertise. The MV platform de...